Phase III Study (MM-020/IFM 07-01) of Oral REVLIMIDA (Lenalidomide)...

Celgene International SA rl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMIDA in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival .

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130711005635&newsLang=en&ndmConfigId=1000639&vnsId=41